Showing results (121-130 of 274) with videos related to
Sort By:
Pageof 28
Oncotarget|February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.The Oncologist|March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA MutationJoseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignanciesShivaani Kummar, Larry Anderson, Kimberly Hill, et al.Journal of the National Cancer Institute|November 5, 2024
The Diverse Aspects of Uterine Serous Cancer: an NCI workshop on the status of and opportunities for advancement of researchNaveena B Janakiram, Megan A Clarke, Mihoko Kai, et al.Anticancer Research|May 5, 2005
Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer modelFrank G E Perabo, André W Demant, Andreas Wirger, et al.Carcinogenesis|October 6, 2007
The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cellsFiona A Simpkins, Nick M Devoogdt, Nabila Rasool, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working GroupLia Gore, S Percy Ivy, Frank M Balis, et al.Cancer|February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation ProgramAlexander Drilon, Anne A Eaton, Katja Schindler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumorsJulie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated ToxicitiesAnne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.Pageof 28